BRICKELL BIOTECH BBI 深 沪
等待开盘 01-23 09:30:00 美东时间
2.35
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 2.35
- 总市值 675.39万
- 52周最高 36.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.21
- 委 比 0.00%
- 总股本 287.40万
- 历史最高 225.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 4.185
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights
Boundless Bio has announced its Q2 2025 financial results, including $127 million in cash, and highlighted progress in its oncology programs. The POTENTIATE trial's BBI-355/BBI-825 combination arm is now open for enrollment, and BBI-940 is on track for IND submission in H1 2026. The company aims to deliver proof-of-concept data for both programs within its current cash runway, supporting operations into H1 2028. R&D expenses were $12.2 million, a...
2025-08-05 11:00
This Healthcare Stock Surges Around 115%, Here's 74 Biggest Movers From Yesterday
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) shares surged 114.3% to close at $0.2550 on Wednesday after the company announced it has terminated its previously announced at-the-market offering.
2022-06-30 16:55
Why Is Allena Pharmaceuticals Jumping By 207%? 45 Stocks Moving In Wednesday's Mid-Day Session
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 207% to $0.3650 after the company announced it has terminated its previously announced at-the-market offering.
2022-06-30 00:32
Brickell Biotech Doses First Subject In Phase 1 Study Of DYRK1A Inhibitor BBI-02
– BBI-02 is a potential first-in-class, oral DYRK1A inhibitor with strong preclinical validation and broad potential to treat debilitating autoimmune and inflammatory diseases – – Topline results from
2022-05-19 20:04
Lake Street Downgrades Brickell Biotech to Hold
Lake Street analyst Thomas Flaten downgrades Brickell Biotech (NASDAQ:BBI) from Buy to Hold.
2022-05-13 21:31
Recap: Brickell Biotech Q1 Earnings
Brickell Biotech (NASDAQ:BBI) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
2022-05-13 05:04
Brickell Biotech Q1 EPS $(0.08) Misses $(0.06) Estimate, Sales $92.00K Miss $140.00K Estimate
Brickell Biotech (NASDAQ:BBI) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.06) by 33.33 percent. This is a 46.67 percent increase over losses of $(0.15) per share from
2022-05-13 04:21
